Related Experiment Video

Updated: Mar 26, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Correlation between Gene Variants, Signaling Pathways, and Efficacy of Chemotherapy Drugs against Colon Cancers

Swarnendu Tripathi1, Louiza Belkacemi2, Margaret S Cheung3

  • 1Department of Biology & Biochemistry, University of Houston, Houston, TX, USA.; Department of Physics, University of Houston, Houston, TX, USA.; Center for Theoretical Biological Physics, Rice University, Houston, TX, USA.

Cancer Informatics
|January 29, 2016
PubMed

Insights

Colon cancer drug efficacy, including oxaliplatin and 5-fluorouracil (5-FU), varies by genetic makeup. Gene variations, particularly in KRAS, correlate with drug response, aiding personalized cancer treatment predictions.

Area of Science:

  • Pharmacogenomics
  • Oncology
  • Molecular Biology

Background:

  • Chemotherapy drugs like oxaliplatin and 5-fluorouracil (5-FU) exhibit variable efficacy and resistance across colon cancer subtypes.
  • Understanding drug response mechanisms at the protein-protein network level is crucial for personalized medicine.

Purpose of the Study:

  • To identify correlations between the activity of oxaliplatin/5-FU and gene variations in colon cancer cell lines.
  • To explore the efficacy of novel platinum-based drugs, such as phosphaplatin, in colon cancer models.
  • To develop a strategy for predicting combination therapy outcomes using pharmacogenomic and molecular data.

Main Methods:

  • Analysis of gene variations from the US National Cancer Institute-60 human cancer cell lines.
  • Correlation analysis between drug activity (oxaliplatin, 5-FU, phosphaplatin) and specific gene variants.
  • Evaluation of protein-protein network interactions in relation to drug response.

Main Results:

  • Specific amino acid variants in KRAS and other colon cancer signaling pathway genes correlate with oxaliplatin/5-FU activity.
  • The novel platinum drug, phosphaplatin, demonstrated comparable efficacy to oxaliplatin and 5-FU against colon cancer cell lines.
  • A combined pharmacogenomic and molecular data approach shows promise for predicting treatment outcomes.

Conclusions:

  • Colon cancer drug efficacy is linked to specific genetic variations, particularly in KRAS.
  • Phosphaplatin represents a potential alternative chemotherapy agent for colon cancer.
  • Integrating pharmacogenomic data with molecular profiles enhances personalized treatment strategies for colon cancer.
Keywords:
KRASchemotherapycolon cancerfluorouraciloxaliplatinplatinum drugs

More Related Videos

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

1.1K
Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal08:00

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

8.0K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
67
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
89